PIVAC 2019

Νew strategies for immune stimulation

9.00–9.30 New strategies to reprogram dysfunctional tumor-infiltrating T cells in paediatric high-risk neuroblastoma D. Fruci (ΙΤ)

9.30–10.00 Tumor ablation and immune stimulation G. Adema (NL)

10.00-10.30 The exercise of TAMing the immune system P.T. Straten (DK)

10.30 – 11.15                              Coffee break

 Immunomodulation via specific targeting

11.15-11.45 The amino acid transporter xCT in breast cancer (stem) cells F. Cavallo (IT)

11.45-12.15 Targeting tumor-specific (neo) antigens: New generation of personalized cancer vaccines C. Gouttefangeas (DE)


 12.15-12.45 Targeting GARP on human Tregs: a novel approach for the immunotherapy of cancer? S. Lucas (BE)

13.00-15.00                                                Lunch

Immunotherapies during Immune senescence        

15.00-15.30 The immune system ages like everything else: what does this mean for cancer immunotherapy? G. Pawelec (DE)

15.30-16.00 NK cell immunosenescence and NK cell-based immunotherapy in AML patients

  1. Solana (ES)


16.00-16.30 Interplaybetween cellular senescence and cancer D. Kletsas (GR)


 Poster Session I

16.30-17.45             Oral presentations of selected posters (10 min each)

Potentiating Cancer Immunotherapies

09.00-09.30 Dissecting T-cell responses in vaccinated, long-term surviving patients E.M. Inderberg (NO)

09.30-10.00 Adoptive T-cell therapy in academia – Oslo experiences G. Kvalheim (NO)

10.00-10.30 Epitope Spreading to Enhance the Effectiveness of TCR Transduced T Cell

M Nishimura (USA)


10.30-11.00                          Coffee break

Poster Session II

11.00-12.30             Oral presentations of selected posters (10 min each)


12.30 – 14.30   Lunch


Immune biomarkers and immunotherapies for hematological diseases

14.30–15.00 Next generation sequencing (NGS) – personalized medicine in haematology A. Madrigal (UK)

15.00–15.30 New treatments for leukaemia A. Madrigal (UK)

15.30 – 16.00 Immunotherapeutic targets for the treatment of adult B-cell acute lymphocytic leukaemia B.A. Guinn (UK)

16.00-16.30 Biomarkers for CLL   K. Stamatopoulos (GR)

16.30-17.00 Immune checkpoint inhibitors for hematological diseases G. Vassilopoulos (GR)

Immune escape and immune suppression

9.00–9.30 Cancer immune escape: MHC expression in primary tumors “versus” metastatic lesion F. Garrido (ES)

9.30–10.00 Role of miRNAs and RNA-binding proteins for the immune escape of tumors Seliger (DE)


10.00-10.45                             Coffee break

10.45-11.15 Myeloid cells assist tumor progression by molecular mechanisms either

dependent or independent from adaptive immunity V. Bronte (IT)

11.15 – 11.45 How do myeloid-derived suppressor cells (MDSC) survive in the inhospitable tumor microenvironment? S. Ostrand-Rosenberg (USA)

11.45-12.15 Dynamic interactions within the tumor microenvironment P. Foukas (GR)

Special Lecture

12.15-12.45 Assessment of Antibody Functional Affinity Using ImmunSpot® G. Kirchenbaum (USA)

12.30-14.30                                    Lunch

15.00 -20.00                             Excursion